In what “appears to be a first for a major drug company,” GlaxoSmithKline “will no longer pay doctors to promote its products and will stop tying compensation of sales
representatives to the number of prescriptions doctors.” A spokesman says the practices involve “tens of millions” of dollars. “We keep asking ourselves, are there
different ways, more effective ways of operating than perhaps the ways we as an industry have been operating over the last 30, 40 years?” CEO Andrew Witty tells Katie Thomas.
Read the whole story at The New York Times »
